

Special Issue

Asymmetric Synthesis and Medicinal Chemistry

Message from the Guest Editor

Any new drug that's chiral is likely to be developed and marketed as a single enantiomer. You win more than you lose with single enantiomers. This statement from an article in Chem. Eng. News emphasized in 2003 the importance of enantiopure pharmaceuticals.

Asymmetric Synthesis and Medicinal Chemistry are areas closely related to each other, and very often fundamental contributions in the development of new asymmetric processes initially disclosed on small scale are transferred in a most impressive way into industrial applications, showing the relevance of those fields for academia and industry alike.

I would like to invite contributions to this special issue of Pharmaceuticals "Asymmetric Synthesis and Medicinal Chemistry" as an opportunity to showcase the creativity of leading scientists to tackle the challenges in the development of chiral drugs.

Guest Editor

Prof. Dr. Oliver Reiser

Institut für Organische Chemie, Universität Regensburg, Universitätsstr.
31, 93053 Regensburg, Germany

Deadline for manuscript submissions

closed (31 January 2010)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/489

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)